WED-042 Use of the ANTICIPATE NASH risk score to stratify patients with compensated MASH cirrhosis: data from a phase 3, doubleblinded, randomized clinical trial assessing the safetyand efficacy of pegozafermin (ENLIGHTEN-cirrhosis)

作者：Juan G Abraldes, Arun J. Sanyal, Rohit Loomba, Quentin M. Anstee, Hank Mansbach, Cynthia L. Hartsfield, Jasmine Dowlat, Laura Contreras, Jennifer B Kang, Shibao Feng, Maya Margalit · 发表于：Journal of Hepatology · 年份：2026 · DOI：10.1016/s0168-8278(26)01606-5 · 研究领域：Liver Disease and Transplantation、Liver Disease Diagnosis and Treatment、Drug-Induced Hepatotoxicity and Protection